The common approach for the treatment of newly diagnosed stage IV NSCLC is to combine platinum-based chemotherapy with PD-(L)1 inhibition, irrespective of tumor PD-L1 status and in the absence of any contraindication to ICI [49]. The gene discussed is CD274; the disease is neoplasm.